XML 18 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail) (USD $)
 0 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 0 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 08, 2014
Program
Jun. 30, 2014
Dec. 31, 2013
Jun. 30, 2014
California Institute for Regenerative Medicine [Member]
Jun. 30, 2013
California Institute for Regenerative Medicine [Member]
Jun. 30, 2014
California Institute for Regenerative Medicine [Member]
Jun. 30, 2013
California Institute for Regenerative Medicine [Member]
Jun. 30, 2014
Beta-thalassemia [Member]
California Institute for Regenerative Medicine [Member]
Jun. 30, 2014
Beta-thalassemia [Member]
California Institute for Regenerative Medicine [Member]
Jun. 30, 2014
License agreement terms [Member]
California Institute for Regenerative Medicine [Member]
Jun. 30, 2013
License agreement terms [Member]
California Institute for Regenerative Medicine [Member]
Jun. 30, 2014
License agreement terms [Member]
California Institute for Regenerative Medicine [Member]
Jun. 30, 2013
License agreement terms [Member]
California Institute for Regenerative Medicine [Member]
Jun. 30, 2014
Biogen [Member]
Product
Jan. 08, 2014
Biogen [Member]
Jun. 30, 2014
Biogen [Member]
Jan. 08, 2014
Biogen [Member]
Jun. 30, 2014
Biogen [Member]
Beta-thalassemia [Member]
Jun. 30, 2014
Biogen [Member]
Beta-thalassemia [Member]
Jan. 08, 2014
Biogen [Member]
Beta-thalassemia [Member]
Jan. 08, 2014
Biogen [Member]
Sickle cell disease [Member]
Jun. 30, 2014
Biogen [Member]
Other Projects [Member]
Jun. 30, 2014
Biogen [Member]
Other Projects [Member]
Jun. 30, 2012
Shire AG [Member]
Targets
Jan. 31, 2012
Shire AG [Member]
Targets
Jun. 30, 2014
Shire AG [Member]
Jun. 30, 2013
Shire AG [Member]
Jun. 30, 2014
Shire AG [Member]
Product
Jun. 30, 2013
Shire AG [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                          
Number of research programs 2                                                        
Upfront license fee                             $ 20,000,000                   $ 13,000,000        
Milestone payments                                 293,800,000     7,500,000 7,500,000                
Number of licensed products approved under agreement                           0                              
Research program to develop laboratory research reagents                               40 months                       6 years  
Deferred revenue   8,842,000 2,282,000                     17,800,000   17,800,000                   7,800,000   7,800,000  
Collaboration agreement related costs and expenses       700,000 500,000 1,000,000 900,000 400,000 700,000                 1,300,000 2,500,000     300,000 300,000     5,600,000 3,700,000 10,400,000 6,800,000
Aggregate number of gene targets                                                 7        
Number of initial gene targets                                                 4        
Number of gene targets                                               5          
Number of additional gene targets                                               2          
Potential amount to be funded for certain Shire milestones                                                       213,500,000  
IND or CTA submission amount                                                       8,500,000  
Number of products approved                                                       0  
Royalty revenue                                                       0  
Revenues under agreement               $ 300,000 $ 700,000 $ 0 $ 300,000 $ 0 $ 700,000